Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
The present invention relates to compounds comprising the general formula (I), in which R 1 and R 2 , which may be identical or different, are selected from the group comprising —H or a linear or branched alkyl group having from 1 to 6 carbon atoms or together form an aromatic or aliphatic ring with 5 or 6 atoms; Y and Z, which may be identical or different, are selected from the group comprising —H, —OH, —COOH, —OR 3 , —CH(OR 3 )COOH, in which R 3 is selected from H, phenyl, benzyl, —CF 3 or —CF 2 CF 3 , vinyl, allyl and a linear or branched alkyl group having from 1 to 6 carbon atoms.
1. A pharmaceutical composition comprising (R)-2-methoxy-3-(4′-aminophenyl)propionic acid, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
2. A method of treating a chronic inflammatory disease selected from the group consisting of Crohn's disease and ulcerative rectocolitis, comprising administering to a mammal in need thereof the pharmaceutical composition of claim 1 .
3. The method of claim 2 , wherein the disease is Crohn's disease.
4. The method of claim 2 , wherein the disease is ulcerative rectocolitis.
5. The method of claim 2 , wherein the mammal is a human.
6. A pharmaceutical composition comprising (S)-2-methoxy-3-(4′-aminophenyl)propionic acid, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
7. A method of treating a chronic inflammatory disease selected from the group consisting of Crohn's disease and ulcerative rectocolitis, comprising administering to a mammal in need thereof the pharmaceutical composition of claim 6 .
8. The method of claim 7 , wherein the disease is Crohn's disease.
9. The method of claim 7 , wherein the disease is ulcerative rectocolitis.
10. The method of claim 7 , wherein the mammal is a human.